Trials / Completed
CompletedNCT04600284
Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102
A Randomized, Open Label, Multiple Dose, Crossover Study to Evaluate Drug-drug Interaction of AD-2101 and AD-2102 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- Male
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2101 and AD-2102 in healthy male subjects.
Detailed description
To evaluate the pharmacokinetic Interaction, safety and tolerability of the combination compared with the administration of AD-2101 and AD-2102.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-2101 | AD-2101 16/5mg |
| DRUG | AD-2102 | AD-2102 25mg |
| DRUG | AD-2101 + AD-2102 | AD-2101 16/5mg + AD-2102 25mg |
Timeline
- Start date
- 2020-11-16
- Primary completion
- 2021-01-20
- Completion
- 2021-04-30
- First posted
- 2020-10-23
- Last updated
- 2021-07-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04600284. Inclusion in this directory is not an endorsement.